CPT® Code 91318

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

The CPT® Code 91318 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a formulation of messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a method that allows the mRNA to be effectively delivered into human cells. The vaccine contains a dosage of 3 mcg in a 0.3 mL volume and is specifically formulated with tris-sucrose to enhance stability and maintain the appropriate pH for storage at refrigerator temperatures. The mRNA included in this vaccine corresponds to the spike protein of the virus, which is a critical component that the immune system recognizes as foreign. Upon administration, the body’s cells utilize the mRNA to produce copies of the spike protein, prompting an immune response that generates antibodies. These antibodies are essential for recognizing and neutralizing the virus if the individual is exposed post-vaccination. This particular code is designated for the supply of the Pfizer pediatric vaccine, intended for children aged 6 months through 4 years, and it is important to note that the administration of the vaccine is reported separately from the supply code itself.